Abstract
Background. Diabetes mellitus is a syndrome of various etiologies, characterized mainly by chronic hyperglycemia with disorders associated with protein and lipid metabolism. Numerous risk factors for the development of type 2 diabetes have been identified, the most important of which is the pathogenetic contribution of visceral obesity. Adipose tissue is now understood to be an active endocrine organ, secreting various hormones and cytokines that regulate metabolism and inflammation. The ADIPOQ gene located on chromosome 3q27, a region that recent scans of the entire human genome have suggested as a “type 2 diabetes susceptibility locus”, encodes the hormone adiponectin, which is derived from adipose tissue. The purpose of the study is to clarify the role of the adiponectin gene polymorphism +45 T>G ADIPOQ rs2241766 in the mechanisms of pharmacogenetic response in patients with obesity and type 2 diabetes, taking into account the assessment of its impact on the course and effectiveness of therapy. Materials and methods. Sixty-one people were selected for analysis. All patients received oral hypoglycemic drugs: sulfonamides, biguanides or their combination before hospitalization in the clinic. A comparative analysis of a number of biochemical parameters was conducted in the groups that took or did not take metformin as the main sugar-­lowering drug, considering the single nucleotide polymorphism of the adiponectin gene. Results. The results indicate that the aforementioned drug has antioxidant properties, a certain hepatoprotective effect (a significant decrease in aspartate and alanine aminotransferase in G allele carriers who received the drug); also, the ability to improve the lipid profile, including in G allele carriers, has been statistically proven, that is, it has the potential to reduce the risk of developing cardiovascular complications, which is the main cause of death in patients. Conclusions. Genetic testing can be used to divide patients with type 2 diabetes and obesity into specific clusters and/or endophenotypes. Advances in the field of pharmacogenomics will allow clinicians to select personalized drug therapy regimens in order to increase its effectiveness and reduce the risk of developing adverse events.

This publication has 35 references indexed in Scilit: